Connectivity maps for biosimilar drug discovery in venoms: the case of Gila monster venom and the anti-diabetes drug Byetta®.
Level 5 - mechanism / opinion, no new human data
In vitro cell culture experiment and bioinformatic connectivity mapping
PubMed 23602926 · doi:10.1016/j.toxicon.2013.03.018
What was done
Researchers treated MCF7 cells with either crude *Heloderma suspectum* (Gila monster) venom or synthetic exenatide (Byetta) to test whether transcriptome profiling combined with Connectivity Map (C-Map) database querying could identify shared drug signatures. Gene expression changes were analyzed using Ingenuity Pathway Analysis and screened against the C-Map reference drug database.
What was found
Both Gila monster venom and Byetta up-regulated shared transcripts (IL-8, ATF-3, NR4A3, RASD1, and EGR-1) and shared insulin-like growth factor 1 (IGF-1) signaling among top canonical pathways. In C-Map screening, Gila monster venom yielded 1,732 positive and 793 negative correlation instances, while Byetta yielded 1,692 positive and 868 negative instances. Both treatments showed positive correlation with the antidiabetic drugs metformin and troglitazone.
Why it matters
This study provides proof of concept that cell-based transcriptomics and connectivity mapping can detect biologically relevant drug-like signatures within crude, complex animal venoms.
Limits
The study was conducted entirely in vitro on a single cell line (MCF7 breast cancer cells), which is not a primary target tissue for metabolic regulation. Whole venom contains complex multi-component mixtures that may produce off-target or confounding expression signatures, and the abstract reports instance counts without statistical effect sizes, significance thresholds, or functional in vivo validation.
Cited by
- supports Exendin-4 was isolated and identified from the venom of the Gila monster.